Medscape

No Clear Effect of Cystic Fibrosis Modulators on Pulmonary Exacerbation Recovery

Modulator therapy does not appear to affect the magnitude of lung function impairment or recovery pattern during pulmonary ...

Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

FDA lifts clinical hold following review of Company’s Complete Response submission.Company expects to restart U.S. enrollment in late 2025 or ...
The American Journal of Managed Care

Disparities in Pneumonia and Fibrosis Mortality Persist Across the US

Mortality rates for pneumonia and pulmonary fibrosis have declined since 1999, but disparities persist by sex, race, and ...
The American Journal of Managed Care

Shared Molecular Pathways Link IPF and RA-Associated Lung Disease

A biomarker panel for IPF may identify RA patients at higher risk for ILD, supporting biological overlap between IPF and ...
Pulmonology Advisor

CHEST: Nerandomilast Slows Decline in FVC in Idiopathic Pulmonary Fibrosis

HealthDay News — For U.S. patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slows the decline in forced vital capacity (FVC), according to a study presented at CHEST 2025, the annual ...